Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent (Q41089628)

26 September 2017

1 reference

title

Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent (English)

1 reference

26 September 2017

1 reference

B N Singh

1

1 reference

26 September 2017

language of work or name

English

0 references

publication date

1 August 1996

1 reference

American Journal of Cardiology

26 September 2017

published in

1 reference

26 September 2017

volume

78

1 reference

26 September 2017

issue

4A

1 reference

26 September 2017

page(s)

41-53

1 reference

The effect of amiodarone, a new anti-anginal drug, on cardiac muscle

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Clinical efficacy of amiodarone as an antiarrhythmic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

The coming of age of the class III antiarrhythmic principle: retrospective and future trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Amiodarone: Historical development and pharmacologic profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Grou

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Effects of amiodarone on thyroid function in patients with ischaemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: significance for the control of sudden cardiac death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Effect of amiodarone on conduction and refractoriness of the His-Purkinje system in the human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Effects of amiodarone, sematilide, and sotalol on QT dispersion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Effects of amiodarone on cardiac and coronary hemodynamics and on myocardial metabolism in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Divergent effects of chronic amiodarone administration on systolic and diastolic function in patients with heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Frequency-dependent electrophysiologic effects of amiodarone in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

A comparison of antiarrhythmic drugs for the suppression of ventricular ectopic depolarizations: A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Amiodarone in refractory life-threatening ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Five-year follow-up of 589 patients treated with amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Therapy of Sustained Ventricular Arrhythmias With Amiodarone: Prediction of Efficacy With Serial Electrophysiologic Studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Implantable cardioverter-defibrillators: not the ultimate gold standard for gauging therapy of VT/fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Are Implantable Cardioverter-Defibrillators Better Than Conventional Antiarrhythmic Drugs for Survivors of Cardiac Arrest?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Implantable defibrillator therapy: does it really prolong life? How can we prove it?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Canadian Implantable Defibrillator Study (CIDS): study design and organization. CIDS Co-Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Evolution of the management of malignant ventricular tachyarrhythmias: the roles of drug therapy and implantable defibrillators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Amiodarone and post-MI patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

The European Myocardial Infarct Amiodarone Trial (EMIAT). EMIAT Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Ventricular arrhythmias in idiopathic dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Class 3 antiarrhythmic action in man. Observations from monophasic action potential recordings and amiodarone treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Efficacy of amiodarone for refractory supraventricular tachyarrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Amiodarone for refractory atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Amiodarone in the management of refractory atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Low-dose amiodarone for atrial fibrillation: time for a prospective study?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900452-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(96)00452-3

1 reference

26 September 2017

1 reference